Peptide–major histocompatibility complex presenting GD2 antigen

The **peptide–major histocompatibility complex (MHC) presenting GD2 antigen** refers to a molecular complex formed when a peptide derived from the disialoganglioside GD2 antigen is processed and loaded onto an MHC molecule, then displayed on the cell surface for recognition by T cell receptors or engineered immune cells. MHC molecules (Class I or II) serve as antigen-presenting receptors: class I MHC presents to cytotoxic (CD8+) T cells, and class II to helper (CD4+) T cells[2][4][6]. GD2 is a tumor-associated carbohydrate antigen highly expressed on several pediatric and adult cancers, including neuroblastoma and melanoma[3][5]. Recent advances in immunotherapy seek to engineer T cells (CAR-T or TCR-T) capable of recognizing tumor-specific peptide–MHC complexes, providing tumor selectivity if the complex is tumor-restricted[7]. However, the nomenclature "Peptide–MHC complex presenting GD2 antigen" is technically incomplete or possibly incorrect, as GD2 is a glycosphingolipid and not classically a direct peptide antigen. Immunotherapies generally target either GD2 itself (with antibodies) or recognize peptide epitopes from GD2-related proteins if processed and presented by MHC. Thus, while the concept of a "Peptide–MHC complex presenting GD2" is used in the context of novel antigen identification, it is not a canonical reference for an established therapeutic target and may reflect an artificial or engineered system. Key points: - **Peptide–MHC complexes** are the primary means of antigen presentation to T cells[2][4][6]. - **GD2** is best known as a glycosphingolipid tumor antigen, not a peptide; direct peptides derived from GD2 are not standard immunotherapy targets[3][5]. - Engineered or artificial systems can present tumor-associated non-peptides (including carbohydrate–protein conjugates or mimotopes) via MHC to generate immune responses, but this is still at an investigational stage[7]. This entry is flagged as "is_incorrect: true" due to an ambiguous or potentially non-canonical naming of the target. The term does not describe a naturally occurring, canonical target molecule or receptor, and GD2 is not a classical peptide antigen presented by MHC in normal physiological contexts.

Other names

Peptide–MHC complex presenting GD2GD2 peptide–MHC complex

Immune recognition and killing of target cells by engineered T cells recognizing the presented GD2 peptide–MHC complex